Kernal Bio
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Cell and Gene Therapy and Genome Editing
Kernal Bio is a VC-backed biotech company pioneering in vivo CAR-T therapies. We harness selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision—ensuring targeted delivery and minimizing off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming inside the body and resulting in B-cell depletion within one week.
Kernal Bio is led by a team with deep expertise from Merck, BMS, MIT, and Harvard, with three FDA-approved therapies and over 120 patents to our name. Based in Boston, MA, we’re backed by Hummingbird Ventures, Amgen, Lilly, HBM, and NVIDIA. In addition to $30M in VC funding, we’ve recently secured $48M in non-dilutive funding to advance our in vivo CAR-T programs.
Company HQ City:
Boston
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2016
Lead Product in Development:
KR-402
CEO
Yusuf Erkul, MD, MBA
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
4
When you expect your next catalyst update?
December 2026
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}